Business Wire

Payment Modernisation Is a Priority for 99% of EMEA Banks in the Next Year, Volante Report Reveals

15.7.2025 10:00:00 CEST | Business Wire | Press Release

Share

Volante Technologies, the global leader in Payments as a Service (PaaS), has released the fifth edition of its annual flagship research report, The Big Survey 2025: Modernising Payments.

The survey of senior-level banking decision makers from 11 countries across EMEA reveals a near unanimous drive for change: 99% of banks plan to implement a new payments solution—replacing one or more systems—within the year, with over half (52%) aiming to do so in the next six months.

Volante found that banks are not only keen to modernise, they are prepared to spend big to future-proof their payments infrastructure. Almost half (49%) of banks surveyed say their budget allocations for payments modernisation have increased over the past 12 months—on average, EMEA banks are planning to spend just under $1.5 million ($1.42 million) on payments modernisation within the next year.

Other survey highlights include:

  • Cost efficiency and resilience are top motivators. Nearly one-third (29%) of banks say cost efficiency and operational resilience are the external factors driving modernisation the most, followed by changing customer expectations for real-time payments and competitive pressure from fintechs and neobanks.
  • Vendor selection is a key concern. The biggest concern for banks in modernising payments is choosing the right vendors and tech partners (38%)—above factors like cybersecurity and fraud risks and budget challenges.
  • Banks are still encumbered by legacy systems. Over a quarter of banks (27%) rely on legacy technology for their payments services—either relying on core banking to provide payments, or using a combination of internally built and / or vendor solutions that are 5-10+ years old.

The survey also revealed that the majority (58%) of EMEA banks use a hybrid approach to cloud adoption for modernising payments, although a quarter are still exploring cloud options but remain mainly on-premises.

However, there is some concern among EMEA banks regarding the process of modernisation. Around a third of banks are concerned about the disruption modernisation may cause, and a similar percentage are worried about the internal skills and knowledge needed to manage the transition. The report notes “the solution to both of these worries is to focus on strategic modernisation: progressing towards modernisation with small, carefully measured steps". It further advises banks that understanding their customers’ priorities is important both in setting out their modernisation roadmap and in building a business case for modernisation and ensuring budgets are tactically spent.

“The fifth edition of The Big Survey shows banks recognise that modernising payments is crucial to survival in the evolving payments landscape. It’s not only market competition and changing customer expectations that are impressing this urgency upon them: 2025 is a pivotal year for regulatory deadlines regarding legislations, such as SEPA Instant Payments and SWIFT ISO 20022,” said Vijay Oddiraju, Co-founder and Chief Executive Officer.

Oddiraju continued, “The fact that banks are preparing to spend, on average, almost $1.5 million on payments modernisation shows that they understand how important it is to adapt to industry shifts. But the size of such modernisation budgets means banks are, understandably, cautious about their selection of vendors and tech partnerships. For banks, the right partners are ones who will help them modernise their payments while lowering risk, improving ROI, and helping them onboard new clients quickly. PaaS providers who can offer banks such solutions, with technology that is resilient, compliant, and easily extensible, stand to win big as payments enters its next era.”

Download a copy of the survey, ‘The Big Survey 2025: Modernising Payments’, here.

Notes to editors

The survey was conducted by Censuswide in May 2025 on behalf of Volante Technologies. All respondents work in banking roles related to payments, transaction banking, corporate banking and wholesale banking and hold director level or more senior positions with responsibility for selecting payment processing systems. Respondents come from 11 different countries: the UK, Portugal, Spain, Saudi Arabia, UAE, Sweden, Norway, Denmark, Belgium, the Netherlands and Luxembourg. Sample sizes varied across countries.

About Volante Technologies

Volante Technologies is the trusted cloud payments modernisation partner to financial businesses worldwide, giving them the freedom to evolve and innovate at record speed. Real-time native, API enabled, and ISO 20022 fluent, Volante's Payments as a Service and underlying low-code platform process millions of mission-critical transactions and trillions in value daily. Volante’s customers include four of the top five global corporate banks, seven of the top ten U.S. banks, and two of the world’s largest card networks. Learn more at www.volantetech.com and linkedin.com/company/volante-technologies.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250715975738/en/

Contacts

On behalf of Volante Technologies:

EMEA
Assyria Graves
Hard Numbers
Tel: +44 7507 870214
VolanteTech@hardnumbers.co.uk

Americas
Julian Byrne
anthonyBarnum
Public Relations
Tel. +1 (512) 665-9258
pr@volantetech.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye